Original-Research, NFON

Original-Research: NFON AG (von NuWays AG): BUY

Veröffentlicht am: 20.11.2026 um 09:01 Uhr | dpa, AD HOC NEWS
Original-Research: NFON AG - from NuWays AG 20.11.2026 / 09:01 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group.

Original-Research: NFON AG - from NuWays AG



20.11.2026 / 09:01 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS
Group.
The issuer is solely responsible for the content of this research. The
result of this research does not constitute investment advice or an
invitation to conclude certain stock exchange transactions.



---------------------------------------------------------------------------



Classification of NuWays AG to NFON AG



     Company Name:                NFON AG
     ISIN:                        DE000A0N4N52



     Reason for the research:     Update
     Recommendation:              BUY
     Target price:                EUR 5
     Target price on sight of:    12 months
     Last rating change:
     Analyst:                     Philipp Sennewald



Q3: decline slowing, margins recovering



Yesterday's Q3 came in line on sales but clearly beat our profitability
estimates. More importantly, the new AI disclosure allows to quantify what
it takes to return to growth. In detail:



Q3 sales of EUR 21.1m (-3.1% yoy, eNuW: EUR 21.1m) marked an improvement vs Q2's
-5.2%. Breaking it down, recurring revenues rose 2% qoq to EUR 20.2m despite
c. 7.5k fewer seats, as ARPU jumped to EUR 10.19 (Q2: EUR 9.95, eNuW: EUR 10.03)
on price adjustments and premium solutions. Seat losses also eased vs Q2 (c.
11.3k), with management confirming the portfolio clean-up to be largely
done. Remaining qoq seat attrition of c. 1% is hence the run-rate to watch,
with the UK (9M sales and seats down close to double digits) as the main
drag.



Margin beat on cost control. Q3 adj. EBITDA rose 7.6% yoy to EUR 3.3m (eNuW: EUR
2.5m), implying a 15.5% margin (+1.5pp yoy) despite lower sales and a
slightly weaker gross margin. The improvement came entirely from opex as
personnel and other operating expenses combined fell EUR 1.2m yoy to EUR 14.9m
in Q3. Part of this is variable, namely lower sales commissions on the
reduced top line, but the bulk reflects the support restructuring and
tighter spending on consulting and external services. In our view, it is
therefore largely sustainable.



First time AI metric disclosure. Intelligent Assistant (EUR 1.7m, +40% yoy,
Q3: +74%) and Customer Engagement (EUR 2.7m, +12%) now account for 7.3% of
recurring revenues (9M'25: 5.8%). Annualised, this adds some EUR 1.5m p.a.,
only half of what PBX currently loses (c. EUR 3m). The way forward hence runs
through the base. With the clean-up completed and a new UK team in place, we
forecast a return to seat growth in FY27e, allowing AI growth to translate
fully into group growth (eNuW: +1.7% yoy). This also widens the upsell
opportunity, as AI embedded in PBX generates only c. EUR 0.6m so far. Key
milestones are quarterly seat development and the FY27 guidance on 25
February.



Guidance looks achievable. Management confirmed its FY guidance of EUR
84.5-86.0m sales and EUR 9.5-10.5m adj. EBITDA. On sales, this implies Q4
revenues of EUR 20.9-22.4m, broadly in line with Q3's EUR 21.1m and with our new
FY26e of EUR 85.3m (Q4e: EUR 21.6m), which looks well covered given the slowing
decline. On profitability, the guidance implies only EUR 1.8-2.8m adj. EBITDA
in Q4, i.e. an 8.0-13.4% margin vs 15.5% in Q3. Simply repeating Q3 would
put FY26 at c. EUR 11m, above the top end of the range. Even accounting for
the one-off-heavy Q4'25 base, we see the mid-point as well within reach (new
eNuW: EUR 10.0m).



Valuation prices in continued decline. Shares trade at 6.9x EV/adj. EBITDA
FY26e, which we regard a deep discount for a 95% recurring, cash-generative
business. While this clearly reflects the shrinking seat base and this
year's guidance cut, the Q3 results point in the right direction. A return
to seat growth in FY27e should thus allow for a re-rating.



Reiterate BUY, unchanged EUR 5.00 PT based on DCF.



READ RESEARCH HERE







You can download the research here:
https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&u=2f5b62821828562d4e47beafba61a2c0
For additional information visit our website:
https://www.nuways-ag.com/research



Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss
bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben
analysierten Unternehmen befindet sich in der vollständigen Analyse.
++++++++++



---------------------------------------------------------------------------



The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
View original content:
https://eqs-news.com/?origin_id=a5aa80ce-e4b7-11f1-b46d-066675bb9927&lang=en



---------------------------------------------------------------------------



2439222 20.11.2026 CET/CEST




Disclaimer...
de | DE000A0N4N52 | ORIGINAL-RESEARCH | boerse | 70539191 |